S*BIO Report issue

For profit Phase 1 Phase 2
Founded: Singapore Singapore (2000)
Status: Acquired by CTI BioPharma (2012) → now Advent International (2021)

Organization Overview

First Clinical Trial
2007
NCT00741234
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

pacritinib (Vonjo) (5 trials)

pracinostat (2 trials)

Drugs in Phase 1 Trials (2)

azacitidine (vidaza) (1 trial)

sb1578 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hodgkin Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Mantle-Cell (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 2)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Preleukemia (Phase 2)

Primary Myelofibrosis (Phase 2)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 4